Oncimmune Holdings PLC (ONC)
LSE LSE Primary Summary
ONC Chart
Oncimmune Holdings PLC (ONC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oncimmune Holdings PLC ever had a stock split?
Oncimmune Holdings PLC Profile
| - Industry | - Sector | Mr. Martin John Gouldstone CEO | LSE Exchange | G6750T108 CUSIP |
| United Kingdom Country | 38 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Oncimmune Holdings plc operates within the immunodiagnostics space, contributing advancements particularly in immuno-oncology, alongside autoimmune and infectious disease detection. With operations extending from its home base in the United Kingdom to North America and Europe, this company engages globally. Since its establishment in 2015, Oncimmune has focused on leveraging the body's immune response towards disease to offer early detection and insightful diagnostics. Headquartered in Leeds, the United Kingdom, Oncimmune is dedicated to pioneering solutions that enhance drug development and patient care in various disease contexts.
Products and Services
- EarlyCDT-Lung
An innovative immunodiagnostic blood test designed for the early detection and identification of lung cancer. This product exemplifies Oncimmune's commitment to improving early cancer diagnosis, aiming to significantly boost the survival rate by identifying cancer at an early, more treatable stage.
- ImmunoINSIGHTS
This service platform is tailored for life science organizations, facilitating the optimization of drug development and delivery processes. ImmunoINSIGHTS offers comprehensive insights into how the immune system interacts with various therapies, providing critical data for enhancing drug efficacy and patient responses.
- SeroTag discovery arrays
A versatile tool for the discovery and validation of biomarkers, crucial for patient stratification across multiple cancer indications, infectious diseases, and various autoimmune disorders. These arrays support Oncimmune's broader mission to personalize medicine, ensuring the right treatments are matched to the right patients.
- NavigAID
A disease-specific panel designed to characterize different diseases, facilitating a deeper understanding of disease mechanisms and patient variability. NavigAID stands as a pivotal component in Oncimmune's arsenal, helping to navigate the complexities of autoimmune diseases and enabling more targeted therapeutic approaches.
